Type C Meeting Requested to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, Feb. 24, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc.
Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...
Political and business leaders are rethinking AI—as not just a technology to regulate but as a force to accelerate. Medicine ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ ...
23h
The Healthy on MSNOTC Medication Mistakes: Doctors Advise You To Avoid Doing TheseJust because you can buy a medication over the counter doesn’t mean it’s always safe. Here’s how you should really be using ...
An approval for the first drug for a rare lipid storage disease, some FDA workers rehired, and other biotech news of the day ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...
Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...
Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results